SCARs Label Warning For OTC PPIs In US Starts With Perrigo’s 131 Omeprazole Product Options
Executive Summary
FDA approves warning for severe cutaneous adverse reactions on labeling for Perrigo's 131 20-mg omeprazole delayed-release tablet products across unflavored and cool mint or wild berry-mint options and 14-, 28- and 42-count packages.
You may also be interested in...
Kidney Inflammation Warning For PPI Omeprazole In Europe
Cases of acute tubulointerstitial nephritis linked to omeprazole use flagged to the EMA leads to new product information warnings related to a possible risk of kidney inflammation for drugs containing the PPI sold in the EU.
US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?
Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.
Rare Skin Allergy Warning Spreads To Nexium 24HR
FDA approves request after Nexium 24HR marketer Haleon responded March to changes-being-effected letter asking for label change to the delayed-release PPI.